医学
氨氯地平
替米沙坦
梅德林
内科学
血压
政治学
法学
作者
Jamshed Dalal,Santanu Guha,Yerramareddy Vijaya Chandra Reddy,Chandrashekhar K. Ponde,Sameer Shrivastava,Rajesh Badani,Shashank Joshi,Arindam Pande,Viveka Kumar,Neeraj Bhalla,Akshyaya Pradhan,Asha Mahilmaran,Nirmal Kumar,Sivaramakrishnan Manoj,Toutem Sashikant,Mainak Mukhopadhyay,Mangesh Tiwaskar
出处
期刊:PubMed
日期:2023-12-01
卷期号:71 (12): 56-61
标识
DOI:10.59556/japi.71.0407
摘要
Hypertension (HTN) remains one of the most important risk factors for cardiovascular (CV) diseases and a leading cause of mortality worldwide. Despite improvement in detection and treatment, poor blood pressure (BP) control rates are observed globally. The situation in India is alarming with only 22.5% of patients maintaining their BP under control. Initiating early and effective treatment for HTN helps control BP within normal limits and reduces associated health risks. In India, currently, there are no guidelines on the choice of dual combination treatment that can be considered an initial treatment for newly diagnosed HTN patients to achieve effective BP control and reduce CV risks.
科研通智能强力驱动
Strongly Powered by AbleSci AI